期刊文献+

依鲁替尼胶囊处方的筛选研究

Study on Screening of Ibrutinib Capsules Formulation
下载PDF
导出
摘要 目的:对依鲁替尼胶囊的处方进行筛选,获得合适的辅料用量。方法 :采用正交设计法分别考查崩解剂、表面活性剂和润滑剂,以溶出度为主要考查指标。结果:辅料中影响胶囊溶出度的主要因素是十二烷基硫酸钠,最优处方组成为交联羧甲基纤维素钠13.2mg,十二烷基硫酸钠13.2mg,硬脂酸镁1.8mg。结论:采用本处方可生产出符合质量要求的产品。 Objective:To get the appropriate amout of excipients,screen the formulation of ibrutinib capsules.Methods:Orthogonal method was performed in order to choose suitable disintegrant,surfactant,lubricant by using dissolution as indexes.Results:The experimental results indicated sodium lauryl sulfate was the chief factor of influencing dissolution of ibrutinib capsules.The optimum formulation was composed of croscarmellose sodium 13.2mg,sodium lauryl sulfate 13.2mg,magnesium stearate 1.8mg. Conclusion:The optimum formulation are reliable.
作者 安日明
出处 《安徽化工》 CAS 2016年第3期13-14,18,共3页 Anhui Chemical Industry
关键词 依鲁替尼胶囊 处方筛选 正交试验设计 ibrutinib capsules formulation screening orthogonal experiment design
  • 相关文献

参考文献5

二级参考文献14

  • 1董志超,蒋雪涛.羟丙基甲基纤维素在凝胶骨架中的含量与水溶性药物释放机制的关系[J].药学学报,1996,31(1):43-47. 被引量:31
  • 22010—0923FT)A批准的吉利德科学公司(GileadSciences,Inc.)的雷诺嗪缓释片(商品名:Ranexa)说明书[EB/OL].http://www.accessdata.fda.gov/drugsatfda—docs/label/2010/021526s0121b1.pdf.
  • 3CV治疗公司.雷诺嗪持续释放制剂[P].中国.99810836.7,2005-03-23.
  • 4齐鲁制药有限公司.盐酸雷诺嗪缓释制剂及其制备方法[P].中国.200510043928.9,2009-09-05.
  • 5FDA依鲁替尼说明书[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf.
  • 6Honigberg L A,Smith A M,Sirisawad M,et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy[J].Proc Natl Acad Sci USA,2010,107(29):13075-13080.
  • 7Pan Z,Scheerens H,Li S J,et al.Discovery of selective irreversible inhibitors for Brutons tyrosine kinase[J].Chem Med Chem,2007,2(1):58–61.
  • 8Cameron F,Sanford M.Ibrutinib:first global approval[J].Drugs,2014,74(2):263-271.
  • 9O’Brien S,Furman R R,Coutre S E,et al.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label,multicentre,phase 1b/2trial[J].Lancet Oncol,2014,15(1):48-58.
  • 10Mathews Griner L A,Guha R,Shinn P,et al.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells[J].Proc Nat Acad Sci USA,2014,111(6):2349-2354.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部